HF10

DRUG3 trials

Sponsors

Mie University Graduate School of Medicine, Takara Bio Inc., University of Utah

Conditions

Carcinoma of the BreastMalignant MelanomaMelanomaNon-CNS malignant solid tumorRefractory Head and Neck CancerSquamous Cell Carcinoma, Skin

Phase 1

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

CompletedNCT01017185

Takara Bio Inc.Carcinoma of the Breast, Malignant Melanoma, Refractory Head and Neck Cancer +1

Start: 2009-08-31End: 2015-03-31Updated: 2019-05-23

Phase I study of intratumoral injection of HF10, naturally occurring mutant of herpes simplex virus type 1

Active, not recruitingJPRN-UMIN000007263

Mie University Graduate School of MedicineNon-CNS malignant solid tumor

Start: 2012-02-01Target: 9Updated: 2026-06-29

Phase 2

Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma

TerminatedNCT03259425

University of UtahMelanoma

Start: 2018-01-03End: 2020-09-25Updated: 2022-06-13

Related Papers

Phase I trial of intratumoral therapy using HF10, an oncolytic HSV-1, demonstrates safety in HSV+/HSV- patients with refractory and superficial cancers.

Journal of Clinical Oncology2014-05-2030 citations